Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Polypoidal Choroidal Vasculopathy (CyPov)
NCT02976194Phase 4Unknown
- Sponsor
- Pusan National University Hospital
- Start
- Nov 2016
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in polypoidal choroidal vasculopathy (PCV) and exudative age-related macular degeneration, sponsored by Pusan National University Hospital. Primary endpoint: Changes of VEGF-A from 8 weeks to 20 weeks. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT02976194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976194.